BTK and mantle cell lymphoma: In particular, the most relevant results have been obtained for anticancer/anti-inflammatory compounds (Table 1), i.e., the recent approval of 5AP Pirtobrutinib, a reversible BTK inhibitor for the treatment of MCL, demonstrates the value of this scaffold for the development of new therapeutic agents.